SBTX - Regeneron to provide Libtayo to Silverback for evaluation of NSCLC candidate

Alernon77/iStock via Getty Images Regeneron ([[REGN]] -0.2%) will supply its Libtayo (cemiplimab-rwlc) monoclonal antibody treatment to Silverback Therapeutics ([[SBTX]] -8.6%) for an evaluation of the latter's SBT6050 in HER-2 expressing non-small cell lung cancer and gastric cancer. Silverback will expand a phase 1 trial to evaluate SBT6050, a member of a new class of targeted immuno-oncology therapies, in combination with the PD-1 Libtayo, in dose expansion cohorts. Libtayo is currently approved as a first-line NSCLC treatment.

For further details see:

Regeneron to provide Libtayo to Silverback for evaluation of NSCLC candidate